Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Eledon Pharmaceuticals Inc
(NQ:
ELDN
)
4.150
+0.560 (+15.60%)
Streaming Delayed Price
Updated: 3:25 PM EDT, Oct 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eledon Pharmaceuticals Inc
< Previous
1
2
3
4
Next >
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
October 29, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
October 29, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
September 11, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) Leading the Way in Monday Trading Based on Percentage Gain
April 22, 2024
Via
Investor Brand Network
Expert Ratings for Eledon Pharma
November 13, 2023
Via
Benzinga
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
September 04, 2024
Enrollment Completed Four Months Ahead of Schedule
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024
August 19, 2024
ELDN stock results show that Eledon Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
August 14, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
July 29, 2024
80 Participants (Two-thirds of Projected Recruitment) Enrolled
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
July 02, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
June 17, 2024
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets.
Via
InvestorPlace
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
June 11, 2024
Although the very idea of millionaire-maker penny stocks implies incredibly high risks, if all cylinders fire, these companies could fly.
Via
InvestorPlace
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
June 03, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
May 17, 2024
Via
Benzinga
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
May 09, 2024
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
May 09, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
May 09, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Nano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
May 07, 2024
Eledon Pharmaceuticals' results from islet cell transplant trial for type 1 diabetes, with tegoprubart showing safety and efficacy in kidney transplant patients. Analysts anticipate significant...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 07, 2024
Via
Benzinga
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
May 07, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
May 07, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
March 28, 2024
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
March 28, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
March 25, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Kidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To Receive
March 21, 2024
Eledon Pharmaceuticals announces successful use of tegoprubart in kidney xenotransplant. Promising results show its potential to prevent rejection, marking a significant milestone in organ...
Via
Benzinga
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
March 21, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
January 04, 2024
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
November 29, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.